ANNX vs. TBPH, NGNE, PEPG, ESPR, SLRN, MREO, VERV, ANL, BMEA, and KRRO
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Theravance Biopharma (TBPH), Neurogene (NGNE), PepGen (PEPG), Esperion Therapeutics (ESPR), Acelyrin (SLRN), Mereo BioPharma Group (MREO), Verve Therapeutics (VERV), Adlai Nortye (ANL), Biomea Fusion (BMEA), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
In the previous week, Theravance Biopharma had 4 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Theravance Biopharma and 2 mentions for Annexon. Annexon's average media sentiment score of 0.69 beat Theravance Biopharma's score of 0.46 indicating that Annexon is being referred to more favorably in the media.
Annexon presently has a consensus target price of $15.33, indicating a potential upside of 194.31%. Theravance Biopharma has a consensus target price of $20.50, indicating a potential upside of 145.80%. Given Annexon's higher possible upside, analysts clearly believe Annexon is more favorable than Theravance Biopharma.
Annexon has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.
99.1% of Theravance Biopharma shares are held by institutional investors. 12.7% of Annexon shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Theravance Biopharma received 292 more outperform votes than Annexon when rated by MarketBeat users. However, 73.33% of users gave Annexon an outperform vote while only 63.40% of users gave Theravance Biopharma an outperform vote.
Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Annexon has a net margin of 0.00% compared to Theravance Biopharma's net margin of -72.79%. Theravance Biopharma's return on equity of -18.97% beat Annexon's return on equity.
Summary
Annexon and Theravance Biopharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
